Novartis Reports Results of BYL719 (alpelisib) + fulvestrant in P-III SOLAR-1 trial for HR+/HER2- Advanced Breast Cancer

 Shots:

• The P-III SOLAR-1 trial assessed BYL719 (300 mg, qd) + fulvestrant (500 mg) vs PBO (fulvestrant) in 572 postmenopausal women in ratio (1:1) with PIK3CA-mutated HR+/HER2- advanced or metastatic breast cancer
• P-III SOLAR-1 trial results: mPFS (11.0 vs 6.8 mos.), additional 1L therapy mPFS (10.9 vs 3.7 mos.), PIK3CA mutation (3% vs 2%), safe and well- tolerated
• BYL719 (alpelisib) is an alpha-specific PI3K inhibitor, for suppressing PIK3CA mutations targeted for HR+/HER2- Advanced Breast Cancer

Click here to read full press release/ article | Ref: Novartis | Image: Fortune